China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 45,019 shares, a decrease of 37.4% from the June 15th total of 71,896 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 50,754 shares, the days-to-cover ratio is presently 0.9 days.

China SXT Pharmaceuticals Stock Down 4.7%

Shares of China SXT Pharmaceuticals stock traded down $0.12 during midday trading on Friday, hitting $2.45. The company had a trading volume of 14,664 shares, compared to its average volume of 36,540. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. The company has a 50 day moving average of $2.04 and a 200 day moving average of $18.54. China SXT Pharmaceuticals has a 52-week low of $1.25 and a 52-week high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million during the quarter.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals in the 3rd quarter worth about $78,000. Virtu Financial LLC increased its stake in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.